Parkman Acquires New Stake in EyePoint
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 16 2026
0mins
Should l Buy EYPT?
Source: NASDAQ.COM
- New Stake Disclosure: On February 17, 2026, Parkman Healthcare Partners disclosed a new acquisition of 1,088,033 shares of EyePoint in the fourth quarter, marking a new investment for the fund, although EyePoint remains outside its top five holdings, representing only 1.89% of AUM.
- Investment Value Increase: This acquisition increased the quarter-end value of EyePoint by $19.88 million, reflecting Parkman's confidence in the biotechnology firm, despite its overall financial status still being in development mode.
- Clinical Trial Progress: EyePoint is advancing its DURAVYU therapy, with two Phase 3 trials for serious retinal diseases enrolling over 900 patients, with topline data expected in mid-2026, which could position it competitively in the crowded ophthalmology market if successful.
- Financial Status Analysis: Despite generating approximately $31 million in revenue for 2025 and posting a net loss of about $232 million, EyePoint ended the year with around $306 million in cash and investments, sufficient to fund operations into late 2027, indicating a strong commitment to R&D.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EYPT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EYPT
Wall Street analysts forecast EYPT stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 11.850
Low
20.00
Averages
31.50
High
43.00
Current: 11.850
Low
20.00
Averages
31.50
High
43.00
About EYPT
EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
EyePoint Sues Ocular for False Claims on Duravyu
- Lawsuit Background: EyePoint (EYPT) has filed a lawsuit against Ocular Therapeutix (OCUL) in a Massachusetts federal court, alleging that Ocular made false or misleading claims about Duravyu's clinical findings, impacting market perceptions of both companies' products.
- Drug Development Competition: Duravyu is currently in late-stage development targeting wet age-related macular degeneration (wet AMD), which is also the focus of Ocular's lead asset, Axpaxli, creating a direct competitive landscape between the two firms.
- Legal Demands: EyePoint seeks an injunction to prevent Ocular from continuing the alleged dissemination of false claims, along with a retraction of statements and financial damages, highlighting its commitment to protecting its reputation and market position.
- Industry Impact: This lawsuit could significantly affect the future market performance of both companies, particularly in the ophthalmic drug sector, where intensified competition may lead to fluctuations in investor confidence regarding their stocks.
See More
EYEPOINT INC - SEC Filing Claims Ocular Therapeutix Made False Statements About EYEPOINT and DURAVYU
Complaint Overview: A complaint has been filed against EyePoint Pharmaceuticals, alleging that the company disseminated false statements regarding its products, specifically related to EyePoint and Duravyu.
Allegations Details: The allegations focus on claims made by EyePoint that are said to misrepresent the efficacy and safety of their therapeutic offerings, potentially misleading stakeholders and consumers.
See More
Parkman Healthcare Partners Acquires New Stake in EyePoint Pharmaceuticals
- New Investment Disclosure: On February 17, 2026, SEC filings revealed that Parkman Healthcare Partners acquired 1,088,033 shares of EyePoint in Q4 2025, amounting to an investment of $19.88 million, indicating strong confidence in the company.
- Ownership Proportion Analysis: As of December 31, 2025, EyePoint represented 1.89% of Parkman's 13F reportable AUM, highlighting its increasing significance within the investment portfolio.
- Impressive Stock Performance: EyePoint's shares surged 93% over the past year, currently priced at $13.20, significantly outperforming the S&P 500's approximately 20% gain, reflecting optimistic market expectations for its future growth potential.
- R&D Progress Outlook: EyePoint is advancing its DURAVYU Phase 3 trials, with topline data expected in mid-2026; if successful, it could secure a competitive position in the ophthalmology market, despite the company currently being in development mode with a net loss of about $232 million in 2025.
See More
Parkman Acquires New Stake in EyePoint
- New Stake Disclosure: On February 17, 2026, Parkman Healthcare Partners disclosed a new acquisition of 1,088,033 shares of EyePoint in the fourth quarter, marking a new investment for the fund, although EyePoint remains outside its top five holdings, representing only 1.89% of AUM.
- Investment Value Increase: This acquisition increased the quarter-end value of EyePoint by $19.88 million, reflecting Parkman's confidence in the biotechnology firm, despite its overall financial status still being in development mode.
- Clinical Trial Progress: EyePoint is advancing its DURAVYU therapy, with two Phase 3 trials for serious retinal diseases enrolling over 900 patients, with topline data expected in mid-2026, which could position it competitively in the crowded ophthalmology market if successful.
- Financial Status Analysis: Despite generating approximately $31 million in revenue for 2025 and posting a net loss of about $232 million, EyePoint ended the year with around $306 million in cash and investments, sufficient to fund operations into late 2027, indicating a strong commitment to R&D.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, indicating a shift in market sentiment that could influence investor decisions and market trends.
- Upgrades and Downgrades: While specific company names and rating changes are not detailed in the report, such adjustments typically have a significant impact on the short-term performance of the affected stocks, prompting investors to pay close attention.
- Market Reaction Expectations: The adjustments made by analysts may trigger market volatility, especially when investor sentiment towards certain stocks is sensitive, potentially leading to increased trading volumes in the short term.
- Impact on Investor Decisions: As analysts revise their views on stocks, investors may reassess their strategies regarding buying or holding these stocks, thereby affecting overall market liquidity.
See More
EyePoint, Inc. Q4 2025 Earnings Call Insights
- Significant Clinical Progress: EyePoint initiated pivotal Phase III trials for DME in Q4 2025, marking a crucial advancement for DURAVYU, with top line data for wet AMD expected in mid-2026, thereby laying a strong foundation for future market potential.
- Strong Financial Position: By the end of 2025, EyePoint reported $306 million in cash and investments, despite a significant drop in Q4 net revenue to $0.6 million from $11.6 million in Q4 2024, primarily due to the recognition of deferred revenue from the YUTIQ licensing agreement.
- Rising Operating Expenses: Operating expenses for Q4 2025 reached $71 million, up from $57 million in the prior year, reflecting increased trial activities for DURAVYU, although the company expects its cash runway to extend into Q4 2027.
- Positive Safety Data: Among 191 patients, DURAVYU exhibited a low adverse event rate, with cataract incidence at 5.8% and vitreous floaters at 5.2%, demonstrating good safety and tolerability, which bolsters confidence for future commercialization efforts.
See More
EyePoint Sues Ocular for False Claims on Duravyu
- Lawsuit Background: EyePoint (EYPT) has filed a lawsuit against Ocular Therapeutix (OCUL) in a Massachusetts federal court, alleging that Ocular made false or misleading claims about Duravyu's clinical findings, impacting market perceptions of both companies' products.
- Drug Development Competition: Duravyu is currently in late-stage development targeting wet age-related macular degeneration (wet AMD), which is also the focus of Ocular's lead asset, Axpaxli, creating a direct competitive landscape between the two firms.
- Legal Demands: EyePoint seeks an injunction to prevent Ocular from continuing the alleged dissemination of false claims, along with a retraction of statements and financial damages, highlighting its commitment to protecting its reputation and market position.
- Industry Impact: This lawsuit could significantly affect the future market performance of both companies, particularly in the ophthalmic drug sector, where intensified competition may lead to fluctuations in investor confidence regarding their stocks.
See More
EYEPOINT INC - SEC Filing Claims Ocular Therapeutix Made False Statements About EYEPOINT and DURAVYU
Complaint Overview: A complaint has been filed against EyePoint Pharmaceuticals, alleging that the company disseminated false statements regarding its products, specifically related to EyePoint and Duravyu.
Allegations Details: The allegations focus on claims made by EyePoint that are said to misrepresent the efficacy and safety of their therapeutic offerings, potentially misleading stakeholders and consumers.
See More
Parkman Healthcare Partners Acquires New Stake in EyePoint Pharmaceuticals
- New Investment Disclosure: On February 17, 2026, SEC filings revealed that Parkman Healthcare Partners acquired 1,088,033 shares of EyePoint in Q4 2025, amounting to an investment of $19.88 million, indicating strong confidence in the company.
- Ownership Proportion Analysis: As of December 31, 2025, EyePoint represented 1.89% of Parkman's 13F reportable AUM, highlighting its increasing significance within the investment portfolio.
- Impressive Stock Performance: EyePoint's shares surged 93% over the past year, currently priced at $13.20, significantly outperforming the S&P 500's approximately 20% gain, reflecting optimistic market expectations for its future growth potential.
- R&D Progress Outlook: EyePoint is advancing its DURAVYU Phase 3 trials, with topline data expected in mid-2026; if successful, it could secure a competitive position in the ophthalmology market, despite the company currently being in development mode with a net loss of about $232 million in 2025.
See More
Parkman Acquires New Stake in EyePoint
- New Stake Disclosure: On February 17, 2026, Parkman Healthcare Partners disclosed a new acquisition of 1,088,033 shares of EyePoint in the fourth quarter, marking a new investment for the fund, although EyePoint remains outside its top five holdings, representing only 1.89% of AUM.
- Investment Value Increase: This acquisition increased the quarter-end value of EyePoint by $19.88 million, reflecting Parkman's confidence in the biotechnology firm, despite its overall financial status still being in development mode.
- Clinical Trial Progress: EyePoint is advancing its DURAVYU therapy, with two Phase 3 trials for serious retinal diseases enrolling over 900 patients, with topline data expected in mid-2026, which could position it competitively in the crowded ophthalmology market if successful.
- Financial Status Analysis: Despite generating approximately $31 million in revenue for 2025 and posting a net loss of about $232 million, EyePoint ended the year with around $306 million in cash and investments, sufficient to fund operations into late 2027, indicating a strong commitment to R&D.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, indicating a shift in market sentiment that could influence investor decisions and market trends.
- Upgrades and Downgrades: While specific company names and rating changes are not detailed in the report, such adjustments typically have a significant impact on the short-term performance of the affected stocks, prompting investors to pay close attention.
- Market Reaction Expectations: The adjustments made by analysts may trigger market volatility, especially when investor sentiment towards certain stocks is sensitive, potentially leading to increased trading volumes in the short term.
- Impact on Investor Decisions: As analysts revise their views on stocks, investors may reassess their strategies regarding buying or holding these stocks, thereby affecting overall market liquidity.
See More
EyePoint, Inc. Q4 2025 Earnings Call Insights
- Significant Clinical Progress: EyePoint initiated pivotal Phase III trials for DME in Q4 2025, marking a crucial advancement for DURAVYU, with top line data for wet AMD expected in mid-2026, thereby laying a strong foundation for future market potential.
- Strong Financial Position: By the end of 2025, EyePoint reported $306 million in cash and investments, despite a significant drop in Q4 net revenue to $0.6 million from $11.6 million in Q4 2024, primarily due to the recognition of deferred revenue from the YUTIQ licensing agreement.
- Rising Operating Expenses: Operating expenses for Q4 2025 reached $71 million, up from $57 million in the prior year, reflecting increased trial activities for DURAVYU, although the company expects its cash runway to extend into Q4 2027.
- Positive Safety Data: Among 191 patients, DURAVYU exhibited a low adverse event rate, with cataract incidence at 5.8% and vitreous floaters at 5.2%, demonstrating good safety and tolerability, which bolsters confidence for future commercialization efforts.
See More
